SOUTH SAN FRANCISCO, Calif., March 19, 2018 /PRNewswire/ -- ShangPharma Innovation Inc., a global venture capital firm focused on filling the critical investment gap that exists for the earliest-stage therapeutic breakthroughs, has expanded its life science incubator by nearly 40 percent and updated the facility with additional state-of-the-art laboratory infrastructure and conferencing space.
"ShangPharma is answering the call for more space and essential resources for healthcare innovators in the San Francisco Bay area," says Walter H. Moos., Ph.D., CEO of ShangPharma Innovation. "This region is brimming with potentially transformative ideas for new drugs, diagnostics and other healthcare discoveries. But without the right support, these ideas run the risk of dying on the vine."
The incubator is co-located with ShangPharma Innovation's venture capital team, which makes seed-stage and Series A investments in life science entrepreneurs, and with Shanghai ChemPartner, a leading contract research organization providing services spanning discovery chemistry, discovery biology and preclinical development through manufacturing for small molecules and biologics.